Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03586453 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03586453 · ClinicalTrials.gov record · last posted 2026-04-29

Osimertinib In EGFR Mutant Lung Cancer

Name: Osimertinib In EGFR Mutant Lung Cancer — clinical trial record (NCT03586453)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2018-08-13

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

Protocol amendment history 3 changes detected by DataLookout

2026-04-30

Trial status changed: Recruiting → Active, Not Recruiting

2026-04-30

Primary completion pushed: 2027-02-28 → 2028-02-28

2026-04-30

Completion pushed: 2028-03-01 → 2028-09-01

Trial Details

NCT Number	NCT03586453
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: AstraZeneca
Conditions	Carcinoma, Non-Small-Cell Lung
Enrollment	30 participants
Start Date	2018-08-13
Primary Completion	2028-02-28 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-29